10 Best Peptides for Muscle Growth

Peptides that promote muscle growth work through a handful of distinct mechanisms: stimulating growth hormone (GH) release from the pituitary, raising IGF-1 levels downstream, or blocking the signals that limit how much muscle you can build. The right choice depends on where your bottleneck sits -- whether you need more GH output, a direct anabolic signal, or myostatin suppression.

This article ranks 10 peptides used for muscle growth by mechanism, evidence quality, and practical fit. Each section is intentionally brief. For dosing protocols, stacking details, and deep-dive pharmacology, follow the links to each peptide's dedicated page.

Quick Comparison Table

The 10 Best Muscle Growth Peptides

1. CJC-1295 (no DAC)

CJC-1295 without the Drug Affinity Complex is a modified GHRH analog that amplifies natural GH pulses without flattening pulsatile release patterns. It is technically a modified GRF(1-29) -- the same 29-amino-acid bioactive fragment as sermorelin, but with four amino acid substitutions that resist enzymatic breakdown by dipeptidyl peptidase-IV (DPP-IV). This modification extends its effective half-life from minutes to roughly 30 minutes, long enough to produce a meaningful GH pulse without sustaining levels artificially for days.

A single subcutaneous injection produced dose-dependent GH increases of 2- to 10-fold lasting six or more days, with IGF-1 elevations of 1.5- to 3-fold sustained for 9-11 days in healthy adults (Teichman et al., 2006). A follow-up study confirmed that pulsatile GH secretion is preserved even under continuous CJC-1295 stimulation, meaning the pituitary does not downregulate in the way it does with exogenous GH (Ionescu & Bhatt, 2006).

Timing matters with the no-DAC version. Most protocols call for pre-bed injection to coincide with the largest natural GH pulse during early slow-wave sleep. A second injection upon waking or pre-workout is common in twice-daily protocols. Injecting within 30 minutes of a meal -- especially one high in carbohydrates or fats -- blunts the GH response because elevated insulin and free fatty acids suppress pituitary output. Fasted injection is standard practice.

Best for: Experienced users who want sustained GH and IGF-1 elevation while maintaining physiological pulse patterns. Frequently paired with a GHRP for synergistic release.

Deep dive: CJC-1295 Peptide Page | CJC-1295 Dosing Guide

---

2. MK-677 (Ibutamoren)

MK-677 is the only oral GH secretagogue on this list. It activates the ghrelin receptor (GHSR-1a) without requiring injections, making it the most accessible option for sustained GH and IGF-1 elevation.

An 8-week trial in obese males showed MK-677 (25 mg/day) increased fat-free mass and basal metabolic rate, with IGF-1 rising approximately 40% above placebo (Svensson et al., 1998). A larger 12-month randomized controlled trial in healthy older adults (ages 60-81) confirmed significant fat-free mass gains, though these did not translate to measurable strength improvements over that period (Nass et al., 2008).

The appetite increase is pharmacological, not incidental. MK-677 activates the same ghrelin receptor that drives hunger signaling in the hypothalamus, and most users report a noticeable appetite surge within 1-2 hours of dosing. Evening dosing can mitigate this since you sleep through the peak hunger window. The glucose concern is equally real: GH opposes insulin action, and sustained elevation via MK-677 can raise fasting glucose by 5-10 mg/dL in some users. The 12-month Nass trial noted transient increases in fasting glucose and insulin resistance markers, particularly in the first two months. Anyone running MK-677 beyond 8 weeks should monitor fasting glucose and HbA1c. On IGF-1 durability, the long-term data is encouraging -- IGF-1 elevation was maintained throughout the full 12-month study period without significant tachyphylaxis, distinguishing MK-677 from hexarelin and other compounds that show receptor desensitization over time.

Best for: Users who want GH elevation without injections. The oral route and once-daily dosing make MK-677 a practical entry point, though appetite increases and glucose effects require active monitoring.

Deep dive: MK-677 Peptide Page | MK-677 Dosing Guide

---

3. Ipamorelin

Ipamorelin is the most selective growth hormone secretagogue in the GHRP family. It stimulates GH release through the ghrelin receptor without meaningfully increasing cortisol, ACTH, or prolactin -- a profile no other GHRP matches.

Human pharmacokinetic-pharmacodynamic modeling showed ipamorelin produces a clean, single-peak GH release that scales predictably with dose (Gobburu et al., 1999). The landmark selectivity study demonstrated that ipamorelin's cortisol and ACTH responses were not significantly different from those seen with GHRH stimulation alone, confirming its cleaner side effect profile compared to GHRP-2, GHRP-6, and hexarelin (Raun et al., 1998).

The practical implications of this selectivity are significant. Cortisol elevation from other GHRPs can interfere with sleep architecture when injected at night -- precisely when you want GH output to be highest. Because ipamorelin does not raise cortisol, it is well-suited to pre-bed dosing without disrupting sleep onset or slow-wave sleep quality. The absence of a meaningful appetite response also makes ipamorelin the preferred GHRP during cutting or recomposition phases, where caloric control is the priority.

Best for: Users who want reliable GH release with the fewest off-target effects. The go-to GHRP for stacking with CJC-1295, especially for those sensitive to cortisol or appetite disruption.

Deep dive: Ipamorelin Peptide Page | CJC-1295/Ipamorelin Dosing Guide

---

4. Sermorelin

Sermorelin is the original synthetic GHRH analog -- a 29-amino-acid fragment of natural GHRH(1-44). It has the longest clinical track record of any peptide on this list, with FDA approval history for pediatric GH deficiency.

A 16-week placebo-controlled trial in men and women ages 55-71 showed nightly GHRH analog administration increased lean body mass in men, along with improved insulin sensitivity and general well-being (Vittone et al., 1997). Sermorelin's clinical profile is well-reviewed as a practical approach to age-related GH insufficiency that avoids the shutdown risks of exogenous GH (Walker, 2006).

Best for: Beginners and users over 40 addressing age-related GH decline. Sermorelin's established safety record makes it a conservative first choice, though newer GHRH analogs like CJC-1295 offer longer duration of action.

Deep dive: Sermorelin Peptide Page | CJC-1295 vs Sermorelin

---

5. CJC-1295 DAC

CJC-1295 with Drug Affinity Complex binds to serum albumin after injection, extending its half-life to roughly 8 days. This creates sustained, steady-state GH elevation rather than the pulsatile pattern seen with the no-DAC version.

The same clinical data applies -- a single injection increased mean GH by 2- to 10-fold for 6+ days and IGF-1 by 1.5- to 3-fold for 9-11 days (Teichman et al., 2006). The albumin-binding technology was identified as producing a 4-fold increase in GH area under the curve compared to native GHRH(1-29) (Jette et al., 2005).

Best for: Users who prefer once- or twice-weekly injections over daily protocols. The DAC version trades pulse control for convenience and sustained baseline elevation.

Deep dive: CJC-1295 DAC Peptide Page | CJC-1295 DAC Dosing Guide

{{VENDOR_CTA:cjc-1295-dac}}

---

6. GHRP-2

GHRP-2 is a potent ghrelin receptor agonist that stimulates GH secretion through both pituitary and hypothalamic pathways. It releases more GH per dose than ipamorelin but also triggers cortisol, ACTH, and appetite responses.

A study in patients with mutated GHRH receptors demonstrated that GHRP-2 can stimulate GH release even when the GHRH signaling system is non-functional, confirming an independent pituitary mechanism (Maheshwari et al., 1999). A phase I pharmacokinetic study in children showed dose-dependent GH release with a well-characterized safety profile (Pihoker et al., 1998).

Best for: Users who want maximum GH output per injection and do not mind increased appetite. Frequently used in bulking phases where caloric surplus is the goal.

Deep dive: GHRP-2 Peptide Page | GHRP-2 Dosing Guide

---

7. GHRP-6

GHRP-6 shares the ghrelin receptor mechanism with GHRP-2 but produces a more pronounced appetite-stimulating effect. It requires endogenous GHRH for maximal GH response, making it highly synergistic with GHRH analogs.

Research confirmed that endogenous GHRH is necessary for most of the GH response to GHRP-6 in humans, explaining why pairing it with a GHRH analog produces substantially greater release than either alone (Pandya et al., 1998). A pharmacokinetic study in nine healthy male volunteers characterized the dose-response relationship and safety profile (Berlanga-Acosta et al., 2012).

Best for: Hard gainers who need the appetite drive as much as the GH boost. The hunger effect is a feature, not a bug, when caloric intake is the limiting factor.

Deep dive: GHRP-6 Peptide Page | GHRH vs GHRP Comparison

---

8. Hexarelin

Hexarelin is the most potent GHRP in terms of acute GH release per dose. It produces the strongest GH spike in the ghrelin receptor agonist class but also carries the highest cortisol and prolactin response.

A dose-response study in healthy humans showed plasma GH increasing dose-dependently after injection, with peak concentrations reaching 55.0 ng/mL at the highest dose within 30 minutes (Ghigo et al., 1994). However, long-term use shows partial desensitization of the GH response, with studies noting attenuated output over weeks of continuous administration (Rahim et al., 1998).

Best for: Short-term protocols where maximum acute GH release is the priority. Not ideal for sustained use due to desensitization concerns. Often cycled rather than run continuously.

Deep dive: Hexarelin Peptide Page | Hexarelin Dosing Guide

---

9. IGF-1 LR3

IGF-1 LR3 is a modified insulin-like growth factor with reduced IGF binding protein affinity, giving it a longer active half-life than native IGF-1. It bypasses the GH axis entirely and acts directly on IGF-1 receptors in muscle tissue.

IGF-1 drives muscle hypertrophy through the PI3K/Akt/mTOR and PI3K/Akt/GSK3-beta signaling pathways, increasing protein synthesis while suppressing catabolic processes (Schiaffino & Mammucari, 2011). Animal research shows a synergistic effect on muscle growth when IGF-1 overexpression is combined with myostatin inhibition, producing greater-than-additive hypertrophy (Hennebry et al., 2017).

IGF-1 LR3 can be administered systemically (subcutaneous) or locally (intramuscular into the target muscle). Systemic injection raises circulating IGF-1 activity broadly. Local intramuscular injection aims to concentrate the anabolic signal in a specific muscle group, though evidence for meaningfully localized hypertrophy is limited -- most of the compound still enters systemic circulation. The hypoglycemia risk with IGF-1 LR3 is real and distinguishes it from every other peptide on this list. IGF-1 activates the insulin receptor at high concentrations, which can drive blood glucose dangerously low, particularly when administered fasted or in combination with insulin. Symptoms include lightheadedness, sweating, and confusion. Users should always have fast-acting carbohydrates accessible and should never combine IGF-1 LR3 with exogenous insulin without medical supervision.

Best for: Advanced users who have already optimized GH output and want a direct anabolic signal at the tissue level. Requires careful blood glucose monitoring due to insulin-like activity.

Deep dive: IGF-1 LR3 Peptide Page

---

10. Follistatin-344

Follistatin-344 works through an entirely different mechanism than every other peptide on this list. Instead of stimulating GH or IGF-1, it binds and neutralizes myostatin -- the protein that actively limits muscle growth.

Gene therapy delivery of follistatin-344 via AAV1 in nonhuman primates produced durable increases in muscle size and strength in the injected quadriceps (Kota et al., 2009). Transgenic pigs expressing human follistatin-344 showed roughly double the skeletal muscle mass of controls (Zheng et al., 2017).

Best for: Theoretical interest and advanced experimental use. Follistatin-344 has compelling animal data for removing the genetic ceiling on muscle growth, but human peptide injection data remains limited. This is the most experimental option on the list.

Deep dive: Follistatin-344 Peptide Page | Follistatin-344 Dosing Guide

---

Stacking for Muscle Growth

The strongest GH release comes from pairing a GHRH analog with a GHRP. This is not theoretical -- the synergy between the two receptor pathways (GHRH receptor + ghrelin receptor) produces GH output greater than the sum of either alone.

Common muscle growth stacks:

• CJC-1295 (no DAC) + Ipamorelin -- The most popular combination. Clean GH pulse amplification with minimal cortisol or appetite disruption. Ideal for recomposition.
• CJC-1295 (no DAC) + GHRP-2 -- Higher GH ceiling with stronger appetite drive. Better suited for bulking phases.
• MK-677 + CJC-1295 -- Oral baseline elevation (MK-677) combined with injectable pulse amplification. Covers both sustained and pulsatile GH patterns.

Timing Protocols

When you inject relative to meals and training directly affects how much GH you release. The two highest-yield windows are:

1. Pre-bed (primary injection): Inject 30-60 minutes before sleep, at least 2 hours after your last meal. This aligns the exogenous stimulus with the body's largest natural GH pulse during early slow-wave sleep. An empty stomach is critical -- elevated blood glucose, insulin, or free fatty acids all suppress the pituitary GH response.

2. Morning fasted (secondary injection): Inject immediately upon waking, before any food. Wait 20-30 minutes before eating to allow the GH pulse to peak. This window is effective because cortisol is naturally high in the morning (providing a catabolic environment that GH can counteract), and insulin is at its lowest after an overnight fast.

Both the GHRH and GHRP should be injected at the same time -- draw both into the same syringe or inject sequentially within a few minutes. Spacing them apart reduces the synergistic effect because peak receptor activation from each compound needs to overlap.

Common Stacking Mistakes

• Stacking two GHRPs together. Running ipamorelin alongside GHRP-2 or GHRP-6 provides diminishing returns because they compete for the same ghrelin receptor. Pick one GHRP and pair it with a GHRH analog.
• Eating too close to injection. Even a small meal 30-60 minutes before injection can blunt GH release by 50% or more. The insulin and blood glucose spike suppress the pituitary response. Fast for at least 90 minutes pre-injection for best results.
• Running MK-677 and a GHRP simultaneously without a GHRH. MK-677 and injectable GHRPs both act on the ghrelin receptor. Combining them has limited additive benefit. If using MK-677, pair it with a GHRH analog like CJC-1295 rather than adding another GHRP.
• Ignoring the somatostatin rebound. After a large GH pulse, somatostatin rises to suppress further release. Injecting more than 3 times per day can hit a wall where somatostatin tone is persistently elevated, reducing net GH output.

Assessing Whether the Stack Is Working

The most objective measure is an IGF-1 blood test drawn at the 4-week mark. IGF-1 is the downstream signal that mediates most of GH's anabolic effects, and it has a stable enough half-life that a single morning blood draw provides a reliable readout. Compare your on-protocol IGF-1 to the pre-protocol baseline. A meaningful response typically shows a 30-60% increase in IGF-1 above baseline. If IGF-1 has not moved after 4 weeks of consistent use, the most likely explanations are degraded peptide (storage or reconstitution error), injection timing too close to meals, or an underlying issue with pituitary reserve.

Subjective markers also track well: improved sleep depth within weeks 1-2, faster recovery by weeks 2-4, and visible body composition changes by weeks 6-8 are all positive indicators.

For detailed protocols, timing, and doses, see our GHRH vs GHRP Stacking Guide.

How to Choose the Right Peptide

Your starting point depends on three factors:

1. Experience level. If this is your first peptide protocol, start with sermorelin or ipamorelin. Both have well-characterized safety profiles and predictable dose-response curves. MK-677 is another beginner-friendly option since it requires no injections.

2. Primary bottleneck. If GH output is low (common after age 35-40), a GHRH analog or GHRP addresses the root cause. If GH is adequate but tissue-level anabolism is lacking, IGF-1 LR3 acts downstream. If you suspect you are near your genetic ceiling, follistatin-344 targets the limiter itself.

3. Practical tolerance. Injection frequency, appetite effects, and cost all matter. MK-677 eliminates needles. Ipamorelin minimizes side effects. CJC-1295 DAC reduces injection frequency. GHRP-6 and GHRP-2 increase appetite, which is useful in a surplus and problematic in a cut.

4. Cost and value. Peptide protocols are not cheap, and cost varies across compounds. MK-677 is generally the least expensive option at roughly $40-60 per month. Injectable secretagogue stacks (CJC-1295 + ipamorelin) typically run $80-150 per month depending on vendor and dosing frequency. IGF-1 LR3 and follistatin-344 are the most expensive due to manufacturing complexity; monthly costs can exceed $200-300. Factor in bacteriostatic water, syringes, and alcohol swabs as ongoing supply costs for any injectable protocol.

5. Realistic expectations. Peptides are not anabolic steroids. They optimize your body's own GH and IGF-1 output rather than introducing supraphysiological levels of exogenous hormones. The practical ceiling for lean mass gain from a well-run secretagogue protocol is approximately 2-4 pounds of lean tissue over 3-6 months in a trained individual. The more meaningful benefits often show up in body composition shifts (simultaneous fat loss and muscle gain), recovery speed, sleep quality, and connective tissue health. Users who expect steroid-like transformations will be disappointed. Users who understand they are restoring natural GH signaling -- particularly those over 35 whose endogenous GH has already declined -- tend to be the most satisfied.

No single peptide is universally "best." The right choice is the one that matches your physiology, goals, budget, and willingness to manage the protocol.

Bloodwork and Monitoring

Running GH-axis peptides without bloodwork is flying blind. You cannot assess whether the protocol is working, whether dosing needs adjustment, or whether metabolic side effects are developing without objective lab data.

Baseline labs (before starting any protocol):

Draw the following before your first injection or dose to establish your personal reference range.

• IGF-1 -- The primary efficacy marker. IGF-1 reflects integrated GH output over the preceding 24-48 hours and is the most reliable single test for confirming that a secretagogue protocol is producing a physiological response. Draw fasted, in the morning.
• Fasting glucose -- GH is a counter-regulatory hormone that opposes insulin action. Baseline fasting glucose gives you a reference point for detecting any metabolic shift during the protocol.
• HbA1c -- A 90-day average of blood glucose control. Particularly important if running MK-677 or any protocol longer than 8 weeks, as chronic GH elevation can impair insulin sensitivity gradually enough to miss on spot checks.
• Fasting insulin -- More sensitive than glucose alone for detecting early insulin resistance. If fasting glucose is normal but fasting insulin is elevated, the pancreas is compensating and the metabolic load may be unsustainable long-term.
• Comprehensive metabolic panel (CMP) -- Covers liver enzymes, kidney function, and electrolytes. Establishes organ function baselines and catches unrelated issues that could complicate the protocol.

Follow-up labs:

Retest IGF-1 and fasting glucose at 4 weeks. If IGF-1 has not increased by at least 20-30% above baseline after 4 weeks of consistent dosing, troubleshoot before continuing -- the peptide may be degraded, timing may be off, or pituitary reserve may be insufficient.

At 8-12 weeks, run the full panel again: IGF-1, fasting glucose, HbA1c, fasting insulin, and CMP. This is the checkpoint for metabolic safety. If fasting glucose has risen more than 10 mg/dL above baseline, or HbA1c has increased by 0.3% or more, reassess the protocol -- consider dose reduction, cycling off for 4-8 weeks, or switching compounds. MK-677 users in particular should treat the 8-week glucose check as non-optional.

For ongoing protocols, repeat the full panel every 3-4 months to ensure metabolic costs do not accumulate silently.

Frequently Asked Questions

Can I stack multiple muscle growth peptides together?

Yes, and stacking is how most experienced users run these compounds. The standard approach pairs a GHRH analog (CJC-1295 or sermorelin) with a GHRP (ipamorelin, GHRP-2, or GHRP-6) because they activate different receptor pathways. Stacking two peptides from the same class (e.g., two GHRPs) provides diminishing returns since they compete for the same receptor.

How long before I notice muscle growth from peptides?

GH-mediated muscle growth is slower than direct anabolics. Most users report improved recovery and body composition changes within 4-8 weeks, with measurable lean mass gains appearing over 3-6 months of consistent use. Sleep quality and recovery speed tend to improve within the first 1-2 weeks -- these are early indicators that the protocol is working.

Is MK-677 as effective as injectable peptides for muscle growth?

MK-677 produces comparable GH and IGF-1 elevation to injectable GHRPs. The 12-month RCT in older adults showed significant fat-free mass gains. However, MK-677 increases appetite more than ipamorelin and can affect glucose homeostasis with prolonged use. For raw GH output per dose, injectable combinations like CJC-1295 + ipamorelin offer more precise control.

Do I need bloodwork while using growth hormone peptides?

Yes. At minimum, check IGF-1 levels (to confirm the peptide is working), fasting glucose and HbA1c (GH raises blood sugar), and a comprehensive metabolic panel. Baseline labs before starting and follow-up at 6-8 weeks is the standard approach. See our peptide-specific bloodwork guides for marker details.

Which peptide is best for building muscle over 40?

Sermorelin or CJC-1295 paired with ipamorelin is the most common starting point for users over 40. Age-related GH decline is the primary bottleneck in this group, and GHRH analogs address it directly without suppressing your own production. MK-677 is a reasonable alternative if you prefer oral dosing. Start with one compound, confirm it works via bloodwork, then consider adding a second.

Related Reading

• Muscle Growth Goal Page -- Overview of all muscle growth peptides and how they compare
• GHRH vs GHRP: Different Receptors Guide -- Deep dive into the two receptor pathways driving GH release
• CJC-1295/Ipamorelin Dosing Guide -- The most popular muscle growth stack protocol
• CJC-1295 vs Sermorelin -- Head-to-head comparison of the two leading GHRH analogs
• MK-677 Dosing Guide -- Oral secretagogue protocol and monitoring

References